These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 33307024)

  • 21. Invitation to Screening Colonoscopy in the Population at Familial Risk for Colorectal Cancer.
    Bauer A; Riemann JF; Seufferlein T; Reinshagen M; Hollerbach S; Haug U; Unverzagt S; Boese S; Ritter-Herschbach M; Jahn P; Frese T; Harris M; Landenberger M
    Dtsch Arztebl Int; 2018 Oct; 115(43):715-722. PubMed ID: 30518470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population screening for colorectal cancer by flexible sigmoidoscopy or CT colonography: study protocol for a multicenter randomized trial.
    Regge D; Iussich G; Senore C; Correale L; Hassan C; Bert A; Montemezzi S; Segnan N
    Trials; 2014 Mar; 15():97. PubMed ID: 24678896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized Controlled Trial Testing Provision of Fecal and Blood Test Options on Participation for Colorectal Cancer Screening.
    Symonds EL; Hughes D; Flight I; Woodman R; Chen G; Ratcliffe J; Pedersen SK; Fraser RJL; Wilson CJ; Young GP
    Cancer Prev Res (Phila); 2019 Sep; 12(9):631-640. PubMed ID: 31266825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of gender-specific invitation letters on utilization of colorectal cancer screening.
    Zhan T; Hielscher T; Eckardt M; Giese T; Schäfer C; Riemann JF; Ebert MP; Belle S
    Z Gastroenterol; 2019 Sep; 57(9):1051-1058. PubMed ID: 31525797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of Behavioral Economics Principles Improves Participation in Mailed Outreach for Colorectal Cancer Screening.
    Bakr O; Afsar-Manesh N; Raja N; Dermenchyan A; Goldstein NJ; Shu SB; May FP
    Clin Transl Gastroenterol; 2020 Jan; 11(1):e00115. PubMed ID: 31972609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening.
    Segnan N; Senore C; Andreoni B; Azzoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; Ederle A; Fantin A; Ferrari A; Fracchia M; Ferrero F; Gasperoni S; Recchia S; Risio M; Rubeca T; Saracco G; Zappa M;
    Gastroenterology; 2007 Jun; 132(7):2304-12. PubMed ID: 17570205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Quarter of Participants With Advanced Neoplasia Have Discordant Results From 2-Sample Fecal Immunochemical Tests for Colorectal Cancer Screening.
    Wieten E; de Klerk CM; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1805-1811.e1. PubMed ID: 31563557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of colorectal cancer screening participation in remote northern Canada: A retrospective cohort study.
    Smith HA; Scarffe AD; Brunet N; Champion C; Kandola K; Tessier A; Boushey R; Kuziemsky C
    World J Gastroenterol; 2020 Dec; 26(48):7652-7663. PubMed ID: 33505142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced and Full-Preparation CT Colonography, Fecal Immunochemical Test, and Colonoscopy for Population Screening of Colorectal Cancer: A Randomized Trial.
    Sali L; Mascalchi M; Falchini M; Ventura L; Carozzi F; Castiglione G; Delsanto S; Mallardi B; Mantellini P; Milani S; Zappa M; Grazzini G;
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26719225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
    Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining fecal immunochemical testing and questionnaire-based risk assessment in selecting participants for colonoscopy screening in the Chinese National Colorectal Cancer Screening Programs: A population-based cohort study.
    Dong X; Du L; Luo Z; Xu Y; Wang C; Wang F; Cao W; Zhao L; Zheng Y; Zhu H; Xia C; Li J; Du M; Hang D; Ren J; Shi J; Shen H; Chen W; Li N; He J;
    PLoS Med; 2024 Feb; 21(2):e1004340. PubMed ID: 38386617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting.
    Akram A; Juang D; Bustamante R; Liu L; Earles A; Ho SB; Wang-Rodriguez J; Allison JE; Gupta S
    Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1265-1270.e1. PubMed ID: 28167157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reinvitation to screening colonoscopy: a randomized-controlled trial of reminding letter and invitation to educational meeting on attendance in nonresponders to initial invitation to screening colonoscopy (REINVITE).
    Pisera M; Kaminski MF; Kraszewska E; Rupinski M; Regula J
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):538-42. PubMed ID: 26967693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colorectal Cancer screening in ambulatory healthcare service clinics in Abu Dhabi, United Arab Emirates in 2015-2016.
    Almansoori A; Alzaabi M; Alketbi L
    BMC Cancer; 2021 Aug; 21(1):897. PubMed ID: 34362343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.